Hope abounds that, after years of rejecting lifesaving medications, the Food and Drug Administration is turning things around ...

BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today reported financial results for the fourth quarter and full year ended December 31, 2025, and highlighted ...

(NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the fourth quarter and full-year 2025. “Following a tumultuous 2025, we entered 2026 ...

In the third quarter, Dyne beat expectations with a loss of $0.76 per share versus the $0.84 consensus estimate. Late last year, the company presented positive topline results for the DELIVER trial in ...

Chugai Pharma introduces “Elevidys” as Japan’s first regenerative medical product for Duchenne muscular dystrophy: Tokyo Monday, February 23, 2026, 11:00 Hrs [IST] Chugai Ph ...

Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy – U.S. FDA Study May Proceed ...

– U.S. FDA Study May Proceed notification enables initiation of clinical trial site activation for the FUNCTION-DMD Phase 1/2 clinical study in patients with Duchenne muscular dystrophy (DMD) – – ...

Honda Motorcycle and Scooter India has finally launched the new Honda Dio 125 X-Edition scooter and Honda Shine 125 limited edition motorcycle in the Indian market, priced from Rs 87,733 and Rs 86,211 ...

A Boxed Warning was included in the prescribing information highlighting the risk of serious liver injury and acute liver failure. The Food and Drug Administration (FDA) has approved new safety ...

Duchenne muscular dystrophy (DMD) causes muscle weakness that becomes more severe over time. While there is no cure, treatments can help slow the progression and manage symptoms and complications.

Capricor Therapeutics is advancing deramiocel (CAP-1002) for DMD cardiomyopathy, with a BLA resubmission and HOPE-3 topline data expected by 2026. CAPR's therapy addresses a critical unmet need in non ...

Duchenne muscular dystrophy (DMD) occurs as a result of genetic changes on the X chromosome. If someone has a gene change that can cause DMD, their children may inherit that change. DMD is a ...